$NFRM is pleased to obtain the exclusive license to the technology on worldwide basis for GLB333. The product that has considerable data already, will be ready for clinical trials Phase I/II in near future," said Elaine Affleck, President of National Pharmaceuticals Corp. http://t.co/6g3n3KI 03/22/11